Paper Details

  1. Home
  2. Paper Details

Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis.

Author: , AbbateAntonio, BrucatoAntonio, CremerPaul, FangFang, ImazioMassimo, InsalacoAntonella, KleinAllan L, LeWinterMartin, LewisBasil S, LinDavid, LuisSushil A, NichollsStephen J, PanoArian, PaoliniJohn F, WheelerAlistair

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This phase 3 trial evaluated the efficacy and safety of rilonacept in patients with recurrent pericarditis. The study found that rilonacept led to rapid resolution of recurrent pericarditis episodes and to a significantly lower risk of pericarditis recurrence than placebo.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Interleukin-1 has been implicated as a mediator of recurrent pericarditis. The efficacy and safety of rilonacept, an interleukin-1α and interleukin-1β cytokine trap, were studied previously in a phase 2 trial involving patients with recurrent pericarditis. METHODS: We conducted a phase ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1056/NEJMoa2027892

データ提供：米国国立医学図書館（NLM）

Rilonacept: A Potential Oasis for Recurrent Pericarditis

The field of cardiology is constantly evolving, with researchers tirelessly searching for new treatments for various heart conditions. Recurrent pericarditis, characterized by repeated episodes of inflammation surrounding the heart, is a challenging condition for patients. This research dives deep into the potential of rilonacept, an interleukin-1 trap, as a therapy for this debilitating disease. This study employed a double-blind, randomized-withdrawal trial design to assess the efficacy and safety of rilonacept in patients suffering from recurrent pericarditis.

A Beacon of Hope for Patients with Recurrent Pericarditis

The results of this study are truly encouraging! The researchers discovered that rilonacept significantly reduced the risk of pericarditis recurrence, with a mere 7% of patients experiencing a recurrence in the rilonacept group compared to a staggering 74% in the placebo group. This is like finding a hidden spring in the vast desert – a source of relief for patients struggling with recurrent pericarditis.

Navigating the Desert of Pericarditis: Finding a Path to Recovery

With these promising findings, rilonacept emerges as a potential oasis in the vast desert of recurrent pericarditis, offering a path to recovery for many patients. However, it's crucial to remember that this is just one study, and further research is needed to fully understand the long-term effects and optimal usage of rilonacept. As with any new treatment, it's important to consult with a healthcare professional to determine if rilonacept is right for you.

Dr. Camel's Conclusion

Rilonacept offers a glimmer of hope for those enduring the cyclical pain of recurrent pericarditis. It's like discovering a cool, refreshing breeze in the heart of a scorching desert. This research is a valuable step toward understanding the potential benefits of rilonacept, but further research is needed to fully navigate the complexities of this fascinating medicine.

Date :
  1. Date Completed 2021-01-21
  2. Date Revised 2021-08-26
Further Info :

Pubmed ID

33200890

DOI: Digital Object Identifier

10.1056/NEJMoa2027892

Related Literature

Article Analysis
・Effects of rilonacept injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.